It is generally agreed that most forms of nephritis probably have an immunologic basis. This belief is supported by a large number of studies focusing on the nephritogenic immune response as it occurs locally within the kidney. One outgrowth of these immunologic investigations is the now classical subdivision of renal histopathology into the effector pathways of antibody [1] [2] [3] , immune deposit [4] [5] [6] [7] , and cell-mediated disease [8] [9] . The thorough study of these effector pathways has greatly enhanced our understanding of the inflammatory mechanisms directly involved in developing immunopathology [8, 10] . There is, however, another aspect to immune-mediated renal disease which is the rapidly growing area of immune regulation. Interest in this subject has emerged as one of several fascinating developments within the field of basic immunology and has been sustained because a variety of experimental observations now suggests that immune regulation has an important role in defining the natural history of an immune response. In the context of renal disease, immune regulation can be viewed as a complex network of antibody and cellmediated circuits usually operating to produce feedback suppression and down-regulation leading to the eventual control of on-going renal injury. The interdigitation of such regulatory systems with the more traditional areas of renal immunology has not been formally defined. As this integration occurs, however, the subject of immune regulation will more than likely find a permanent and, perhaps, prominent place within the broader view of the nephritogenic immune response.
It is interesting to observe from a historical perspective that the complexity of the immunoregulatory process during renal injury was not initially appreciated. Prior to its present status immune regulation was viewed in much simpler terms. The modern study of immune-mediated renal disease, for example, was primarily influenced many years ago by Burnet's theory of clonal selection [11] . Simply stated this theory predicted that a new antigen bound to pre-existing lymphoid cells would cause them to proliferate and secrete antibodies. In competition for antigen only those cells with high affinity receptors for the antigen continued to proliferate. Free high affinity antibody united with antigen either in the body fluid or within parenchymal tissues preventing the further stimulation of antigen-reactive clones. In this way antibody removed antigen, thus acting as a negative feedback system, and the lymphocyte clones with high affinity receptors remained as a memory for long-lasting immunity. It is perhaps a measure of the great influence of Burnet's theory that nephrologists traditionally have viewed most aspects of the nephritogenic immune response only in terms of antigen-antibody interactions. The existence of more complicated regulatory processes, including the role of the cellmediated immune response, have all slowly evolved out of a background set in the clonal selection theory. It is only now becoming clear that the humoral and cell-mediated immune responses are closely interrelated at many functional levels. There is no better example of this interplay than in the area of immune regulation. Out of this integrative complexity it would also not be surprising to find that regulatory networks may provide new and additional pathogenic pathways for immunemediated renal disease (Fig. 1) . That is, defects or alterations in regulatory systems may create a permissive environment for the uncontrolled expression of effector responses producing renal injury [12-241. Furthermore, correcting such alterations in immune regulation may provide another direction for therapeutic interventions intending to reduce host morbidity. It is the purpose of this review to relate recent observations in the area of immune regulation to the development of nephritis. Within this framework we will focus on the concepts of T cell function and the role of anti-idiotypic immunity in the control of the nephritogenic immune response.
Immunologic circuits and the network theory of immune regulation A normal individual does not destroy his own parenchymal tissues because immune mechanisms capable of producing such injury are specifically inhibited by regulatory systems acquired during ontogeny [25, 26] . The early evolution of tolerance to these self-determinants has an important selective advantage for the organism [27, 28] . Regulatory systems during life are also activated following the exposure of the immune system to new antigens. Their effectiveness measurably influences, among other things, the overall level of activity of the mediators that may produce chronic inflammation. The actual mechanism regulating the immune response to complex antigens is determined to a large extent by the T cell repertoire. T cells can be divided into subpopulations or sets of lymphocytes displaying different functions. Such subpopulations can be distinguished by cell-surface markers encoded by genes activated during thymic differentiation [12, [29] [30] [31] [32] . Helper/inducerT cells (Ly l in the mouse; OKT4 in the human) can induce B cells to make antibodies, other mononuclear cells to participate in delayed hypersensitivity reactions, and killer cell precursors to become cytotoxic effector cells. Suppressor T cells (Ly 2,3k in the mouse; OKT5/8 in the human) can inhibit both humoral and Antigen L presentation I Fig. 1 . Presentation of a new antigen to the immune system. The ability to make an immune response principally depends on whether or not the host has the appropriate immune response genes. When these immune response genes are present, antibodies, immune complexes, and/or a cell-mediated immune response may ensue. These mediators of immunopathology are balanced by a concomitant regulatory response which provides the control necessary to avoid major target organ damage during the countless self-limited immune reactions generated by the host within its environment. The regulatory mechanism comprises a complex network of T cells and antibodies coordinated as an antiidiotypic immune response. These regulatory responses will be illustrated more fully in subsequent figures. more mature helper or suppressor cells. The helper T cell is the pivotal cell required for activating and expanding the immune response. Once this process is begun all three groups of cells subsequently function as a dynamic modulating unit which normally feeds back to down-regulate or suppress the antigeninduced immune response (Fig. 2) . As an example, a helper T cell activated by a conventional antigen stimulates the development of a variety of effector cells for the purpose of carrying out the immune response. A subset of these helper cells, however, also induces a suppressor cell from the intermediate pool of cells [12, 33] . This new suppressor cell eventually inhibits the immunologic activity stimulated by the original helper cell.
Within this complicated interplay, such T cell interactions can also influence which of the responding lymphocyte clones best recognizes the antigen [34] as well as control the intensity and duration of an enlarging immune response [35, 36] . While some of these immunologic circuits may operate through cell to cell contact, there is growing evidence that much of network communication is accomplished by soluble lymphokines released by activated cells. There are two general groups of these lymphokines; those which are antigen-specific and those which are not. Of the latter group the interleukins have received much attention. Interleukin 1 is an accessory cell-derived peptide which prepares a T cell to respond to its antigen [37] . It also induces the secretion of helper T cell-derived interleukin 2, a soluble lymphokine which can amplify an antigen-reactive immune response by recruiting other helper T cells [38] . These nonspecific lymphokines are essential for successful T cell activation. Specific communication between antigen-reactive lymphocytes, however, is largely accomplished by signals derived from soluble antigen-specific helper and suppressor factors. These specific factors are released by appropriately activated cells and, in many cases, function only according to genetically defined rules [39, 40] .
Which individuals of a species make a T cell response to a particular antigen is determined, in part, by the immune response genes carried in their major histocompatibility complex (MHC) [4 1-43] (See Appendix of this review for complete glossary.). Such genes also play an important role in determining the susceptibility to autoimmune disease [44] . Immune response genes exert their influence by providing gene products for modulating or influencing two basic lymphocyte functions: those of intensity and those related to restriction. Intensity of an immune response is relatively easy to conceptualize while restriction is slightly more difficult. The intensity of an immune response is genetically determined not only by the presence of antigen-reactive lymphocytes, but also by the relative balance between helper and suppressive influences [45] . Restriction refers to the fact that T lymphocytes recognize relevant antigens only when they are presented to the T cell in the context of certain gene products and not in the presence of others. So, for example, if a T helper cell is going to respond to its antigen, this antigen must be processed by an accessory cell and seen in association with certain class II MHC antigens (I region in the mouse; HLA-DIDR region in the human) which are also expressed on the surface of these antigen-presenting cells [46] [47] [48] [49] .
In a similar fashion, for cytotoxic T cells to lyse their target they, too, must see their antigenic determinant in relation to selected class I MHC antigens (KID regions in the mouse; HLA-A,B,C regions in the human) found on the target cell surface [47, 50, 51] . These restriction requirements, as a group, provide important activation or control signals for potential T cell immune responses to complex antigens.
When helper T cells are activated following antigen-recognition, a number of responding clones are initially involved. Their receptors for the antigen have varying degrees of affinity for that antigen and this variability is distributed among the responding clones. If each of the responding helper T cells induces a variety of suppressor T cells, effector T cells, and B cells that all see only one molecular region of an antigen, and, if the antigen has many molecular determinants which will activate different groups of T and B cells, one has to wonder how the individual responding members of the immune system can all communicate with one another and, in a larger sense, how the immune system can regulate this breadth of activity. There is a growing belief that a large part of this coordination is probably the direct result of the anti-idiotypic network [52] [53] [54] [55] [56] .
The discovery of idiotopes and what the immune system does with these idiotopes are recent observations with important implications for the regulatory process. Idiotopes are unique protein determinants which appear within the T cell receptor and in or near the antigen-binding variable region of the antibody molecule. An idiotype identifies the total collection of all idiotopes expressed by these immune products (Fig. 3) . Idiotypic determinants are encoded by variable region genes [56, 57] , and B or T lymphocyte subpopulations responding to a particular molecular region of an antigen will share similar idiotypic determinants. These idiotypes are called individual idiotypes because they are shared by a very limited number of immune cells [56, 58] . Consequently, they also serve to distinguish between the many different clones of T and B lymphocytes participating in the overall immune response. Because an individual idiotype is so unique, it is unlikely to have ever been seen by the immune system prior to antigen-recognition. When clones of antigen-reactive cells start to expand, these idiotypes are processed by the immune system as new antigens. That idiotypes can be immunogenic means that T cell receptors and antibody molecules not only bind antigens but can become new antigens themselves, There is, of course, a second kind of idiotype called a common or cross-reactive idiotype [54, 56] . In some immune responses this cross-reactive idiotype is shared by many different groups of clones responding to an antigen. In this case each of the clones in the group expresses an individual idiotype, but also share common idiotypes. Cross-reactive idiotypes are different than individual idiotypes because crossreactive idiotypes can be recognized by the immune system prior to the introduction of antigen. This occasionally occurs because common idiotypes are more represented among potential antigen-reactive clones than any individual idiotype. Furthermore, such cross-reactive idiotypes may be ideal regulatory molecules as one anti-idiotypic repertoire could control the activity of many clones [54] .
The immune response made to idiotypic determinants is referred to as anti-idiotypic and results in the production of antiidiotypic antibodies and idiotype-reactive cells [56] . Because idiotypes are encoded by variable region genes, they can also share the molecular structure of the antigen-combining site of the primary antibody or T cell receptor. One by-product of this molecular relationship is that some anti-idiotypic immune products will resemble or represent an "internal image" of the inciting antigen [52, 59, [60] [61] [62] . In Figure 3 this is visually symbolized by comparing the box-like structures representing both the antigen and the anti-idiotypic immune products. It should be pointed out, however, that only some of the antiidiotypic immune products might be expected to resemble the antigen [59] . Nevertheless, such observations leave one with the provocative thought that the anti-idiotypic repertoire of each individual might already contain molecular representations of most conventional antigens we are likely to encounter in our environment [52, 59, 60] . The implications of these considerations are several: (1) It would seem that most conventional antigens are not really so foreign; (2) because antiidiotypic antibodies may be recognized as antigen, it is possible that regulatory processes already exist prior to external antigenic challenge; (3) exposure to an external antigen may only upset this dynamic regulatory process with the net result depending on the responding composition of opposing forces, and; (4) in disorders of immune regulation, antibodies mimicking selfantigens may be able to initiate immunologic injury. The control mechanisms and signals which operate this integrated network are largely undefined. Whether cross-reactive idiotypes are functionally more important to the regulatory process than individual idiotypes is still unclear [59, 60] .
The actual development of an anti-idiotypic immune response The induction of this anti-idiotypic immune response is initiated by an idiotype-reactive helper T cell which leads to the production of anti-idiotypic antibodies and idiotype-reactive suppressor T cells. Both the antigen-reactive and idiotype-reactive suppressor T cells eventually limit the expansion of the antigen-reactive immune response. These suppressor cells are modulated by anti-idiotypic antibodies and idiotypically-defined suppressor factors. Although anti-idiotypic antibodies can bind idiotype found on antibodies, its major modulatory effect is probably through the cell-mediated network. The final suppressive signal (thick black lines) has not been formally established but is probably cell-mediated. The suppressive signals produced by antigen and idiotype recognition tend to down-regulate this complex response to antigen and, thus, serve the general economy of the host.
is as complex as the immune response to the original antigen. This second-order immune response is often marked by the appearance of anti-idiotypic antibodies [56] . Antibodies expressing idiotype can exist in the circulation as complexes with anti-idiotypic antibodies [63] , and even as renal immune deposits [14] . Anti-idiotypic immunity can be immunoenhancing [64, 65] but is generally suppressive [54, [64] [65] [66] such that the immunologic function of the lymphocytes expressing the idiotype usually declines with the appearance of anti-idiotypic regulation [56] . The actual mechanism, however, for downregulating the activity of lymphocytes expressing certain idiotypes is not necessarily by the direct neutralizing effects of antiidiotypic antibodies [67] . The mechanism of anti-idiotypic suppression, in many cases, appears to be mediated by a complex interplay between antigen-reactive and idiotype-reactive suppressor T cells (Fig. 3) . These suppressor T cells are modulated by idiotypically-defined suppressor factors as well as by antiidiotypic antibodies [56, 64, 66] . The final suppressive signal that inhibits the antigen-reactive immune response is still unresolved. In some experimental systems it may be mediated by a suppressor T cell effect [66] . These suppressor systems collectively operate as if they were closely interrelated, coordinated, and precise enough to tightly control expanding clones of antigen-reactive lymphocytes.
Thus, the effectiveness of the regulatory response depends on the accurate recognition of complementary cell-surface receptors. The coordination of this network is generally quite good so that under normal circumstances perturbations of the immune system by antigen can be controlled internally to efficiently diminish the development, relative availability, or chronic expression of detrimental mediators of immunopathology. mental animals. These observations form the basis for looking at immunoregulatory function in humans, a subject which will be discussed later. Because this area of research is so new it is natural to expect that much of the information will be incomplete. The examples used in this text are cited to illustrate selected points about the regulatory process in experimental glomerulonephritis, interstitial nephritis, and transplant enhancement. Before each of these renal problems is discussed separately, it would be useful to consider a frame of reference from which the principles of immune regulation can be applied to the development of renal injury. The regulatory process can theoretically influence the development of immune-mediated renal disease in two general ways. First, an expected regulatory response to a nephritogenic antigen could be delayed or fail to appear [20, 23] . In this instance the immune response cannot be terminated and, under such circumstances, a progressively destructive lesion would be expected. Second, a component cell or mechanism in the normal regulatory process could cease to operate or fail to develop such that any number of autoreactive immune responses would spontaneously arise to produce mediators of renal injury [12, 15, 18, 19, 21, 24] . A rather straight-forward illustration of the latter situation can be demonstrated in mice experimentally depleted of T cells ( Table 1 ). Mice that only have B cells and monocytes cannot make T celldependent immune responses, nor do they usually demonstrate any obvious pathology commonly equated with autoimmune disease [12] . If these B cell mice are reconstituted with T helper cells (Ly 1 + cells), a variety of autoantibodies are then produced, and their kidneys accumulate immune deposits produc- [16, 18, 79] . Some of these defects are unique to a particular strain and suggest that the immunologic basis for immune complex disease may be very heterogenous [18] . In all of these mice a number of immunologic aberrations in T and B cell functions have been associated with the development of immunopathology [13, 16, 18] . Several of these strains exhibit a hyperactivity of B cell function [80, 81] as well as produce a wide array of autoantibodies to polynucleotides, phospholipids, and other compounds. Some of these antibodies have a common specificity for sugar-phosphate ligands which comprise portions of many of these self-antigens [17, 82] . This latter observation suggests that the apparent heterogeneity of autoantibodies produced by these mice is not nearly as great as was once assumed. Defects in the regulation of T cell function have also been observed which may further aggravate B cell hyperactivity [12, 18, 83, 84] . Recent experiments indicate that NZB mice have a malfunction in the intermediate T cell (Ly, l,2,3) which provides suppressor cells responsible for feedback suppression (Fig. 4) [12] . MRL/l autoimmune mice have a circuit defect in a completely different site in the feedback system. In these mice the helper cell (Ly l) is capable of inducing antibody production and feedback suppression but is unable to respond to the suppressor signal. Preliminary evidence in the BxSB mouse indicates even a different regulatory defect than in the MRL/l and NZB strains of mice. Here it appears that I helper cells fail to induce the intermediate cell to provide inhibitory activity. While some studies have not always found a T suppressor cell defect in autoimmune mice [85-881, several other investigations have reported that such deficiencies may ultimately contribute to potential failures in T cell modulation [12, 13, 18, 35, [89] [90] [91] [92] . Furthermore, most of the evidence in support of a suppressor cell defect has only been obtained during the primary immune response, and the abnormality seems more related to nonspecific T cell functions [16] . In NZB mice this suppressor T cell defect can be attenuated by passively transferring into nephritic mice a lymphocyte-derived suppressor factor [93] . Treatment with this factor significantly prolongs survival and markedly diminishes the autoimmune disease. T cells of older MRL/1 mice also seem to exert an excessive helper cell activity [12] . This finding is consistent with the observation that disease in MRL/l mice improves with thymectomy [94, 95] and suggests that alterations in both suppressor and helper I cells may operationally increase B cell function in this strain. NZB/W mice, however, worsen following thymectomy [94] . Presumably this is because their suppressor T cell defect, aggravated by thymectomy, can no longer control a hyperactive B cell repertoire. All of this information collectively implies that a variety of different mechanisms underlie the regulatory disturbances found in these mice [18] . None of the above findings, however, clearly illuminates a fundamental basis for the autoimmune response. From a genetic view no one gene can yet account for all immunologic defects seen during the course of disease [16, 18, 79] . Several recent studies nevertheless provide some molecular clues which may further influence our understanding of autoreactivity. Genetic studies in NZB mice now suggest that autoantibody production does not necessarily depend on B cell hyperactivity [96, 97, 99, 100] . If this is true then an alternative explanation for autoantibody production is required. One possible explanation may be derived from studies examining anti-idiotypic immunity in these autoimmune mice. For example, it now appears that NZB mice cannot make an anti-idiotypic immune response to certain antigens [98] including some autoantibodies [15] . If, however, NZB mice are hybridized to other normal strains, the F1 hybrids spontaneously produce an anti-idiotypic immune response which suppresses the production of some autoantibodies [15] . These findings collectively implicate a regulatory abnormality in autoimmune mice which, under normal circumstances, would control autoreactive lymphocyte clones expressing certain variable region gene products (Fig. 5) . To look at this situation more closely, clonal analysis of the anti-DNA antibody repertoire has been performed in NZB/W mice using hybridoma technology [99] . In this study 12 different clonotypes of anti-DNA antibodies were recognized in 13 clones generated from a fusion of a single mouse spleen. This places the total anti-DNA clonal repertoire in the NZB/W mouse at 80 different clonotypes when projection analysis is used, While 12 of the 13 clones were different in some way, eight of the 13 clones shared a common idiotype indicating that some parts of the variable regions of these antibodies were conserved and related. A common or cross-reactive idiotype was also observed among monoclonal anti-DNA antibodies derived from MRL/l mice [101] . Finding a common idiotype among autoantibodies suggests that parts of the variable regions of these antibodies are defined by germ-line genes [17, 101] . Furthermore, the defective regulation of autoantibody expression in these mice may be the result of a failure to provide an appropriate anti-idiotypic repertoire for the down-regulation of these germ-line gene products [19] .
Although a particular anti-idiotypic repertoire may not develop naturally, this does not imply that it or a similar repertoire cannot be induced by another means. In this regard a recent study was performed in autoimmune mice to determine if a relatedness among idiotypes could be used to regulate the expression of autoantibodies [102] . A monoclonal antibody to double-stranded DNA expressing a high-frequency idiotype was repetitively injected into cohorts of NZB/W mice. Serial measurements indicated that mice treated in this fashion had significantly delayed death from nephritis and lower titers of antibodies to double-stranded DNA. These injections of a monoclonal antibody were shown by isoelectric focusing to elicit anti-idiotypic antibodies against the injected anti-DNA antibody. It would be of further interest, of course, to know if this anti-idiotypic immunity could be transferred to untreated mice with suppressor T cells. The anti-idiotypic immune response induced in treated mice more than likely involves a process more complex than the simple induction of antiidiotypic antibodies. Other mechanisms of disease suppression might also be equally involved. In conclusion, autoimmune mice seem to have multiple defects in their immunoregulatory systems. These defects become more obvious with age and MRLI, and BxSB). These mice exhibit a variety of genetic defects which underly a wide spectrum of immunoregulatory disturbances. No one genetic defect, however, totally explains the natural history of their immune complex disease. The immune repertoire in these mice is altered such that autoantibodies appear in association with, but not necessarily related to, the hyperactive function observed among B cells producing immunoglobulin. These mice also have a variety of suppressor T cell defects which probably contribute to the overall regulatory disturbance. In some strains of autoimmune mice there is a recognized defect in antiidiotypic regulation which could be predicted or suspected from the failure to generate primary suppressor cell signals. As B cells producing autoantibodies may share a common idiotype (at least in the case of anti-DNA antibody secretion), one hypothesis to explain the production of autoantibodies may be the failure to produce a regulatory antiidiotypic immune response against these common idiotypes. The result of such a failure, in the presence of other genetic disturbances, might be the generation of immune complex disease. More data is needed to clarify this supposition. While it is possible to induce anti-idiotypic immunity in this experimental model of interstitial nephritis, it would also be interesting to know if such a regulatory immune response normally develops during the course of disease. From recent experiments, however, there is little evidence that this, in fact, does occur [23] . Sera periodically obtained from nephritic animals over the course of 100 days failed to demonstrate the presence of anti-idiotypic antibodies when compared with sera containing anti-idiotypic antibodies against polyclonal idiotypes, or with sera from animals immunized with a relevant monoclonal anti-tubular basement membrane antibody. It is possible that part of this apparent failure to develop antiidiotypic immunity during the course of experimental interstitial nephritis may be related to the concomitant development of polyclonal T cell suppression [23, 109, 110] . Since the recognition of idiotypic determinants and the production of antiidiotypic immunity is a T cell-dependent event [Ill] , polyclonal T cell suppression in a nephritic animal might make an antiidiotypic immune response unlikely (Fig. 6) . To look at this more closely, normal rats were immunized with monoclonal antitubular basement membrane antibody-coated spleen cells and then challenged 5 days later with the same antibody to produce a delayed hypersensitivity response in the footpad [23] . When rats also receive T cells from nephritic animals at the time of immunization with the antibody-coated spleen cells, the delayed hypersensitivity response was abrogated. T cells from nephritic animals also blocked a similar delayed hypersensitivity response to other irrelevant antigens, suggesting that the development of anti-idiotypic immunity could be thwarted by polyclonal suppression. These findings raise the important question of whether anti-idiotypic immunity and its protective effect can be induced after the disease is present. This question has been partially answered in NZB mice [102] but remains an open issue in autoimmune conditions characterized by the development of polyclonal suppression.
Finally, the subject of idiotype regulation has received renewed interest in the area of renal transplantation. The still elusive goal of organ allografting is to develop an effective mechanism to induce specific unresponsiveness in the recipient for donor alloantigens. The induction of specific unresponsiveness, in theory, would still leave the immune system capable of protecting the host from infection and tumors by obviating the need for nonspecific immunosuppressive drugs. Such unresponsiveness to donor alloantigens would also attenuate the nephritogenic immune response leading to allograft rejection [1 12-1 14] . There is probably more than one means for inducing the immunologic enhancement (tolerance) of renal allografts [115, 116] . One potential mechanism of unresponsiveness would be for the recipient to develop an anti-idiotypic immunity to idiotypes expressed by its own alloreactive clones (Fig. 7) . Such a hypothesis was examined in rats pretreated with antidonor serum [117] . Although cellular infiltrates appeared in the transplants of these pretreated recipients, the severe vasculitis associated with rejection was not observed; grafts in enhanced recipients survived for extended periods of time. The state of enhancement was characterized by low levels of cytotoxic reactivity among splenic lymphocytes and by the appearance of serum-blocking factors thought, perhaps, to beimmune complexes or anti-idiotypic antibodies. These studies were extended in a slightly different protocol where rats were pretreated both with donor lymphocytes and antidonor serum [118] . Ten days after this treatment anti-idiotypic antibodies were detected in the serum of the recipients. If renal allografting was performed at this time, enhancement occurred and rejection was avoided for the duration of the study period. Furthermore, no antidonor reactivity was observed in the spleens of these recipients and, of additional interest, enhancement persisted despite the gradual fall in anti-idiotypic antibody titers. Using a similar enhancement protocol, it was also observed that adoptively transferred thymocytes harvested from enhanced and organ-engrafted donors could significantly prolong the survival of other grafts in syngeneic recipients [119] . The enhancing effect was limited to transplants among MHC haplotypes used in the original enhancement protocol, and the transferred suppressor cells have not as yet been identified as either antigen-reactive or idiotype-reactive. If rats are pretreated with donor lymphocytes and monoclonal antibodies to class I or II MHC antigens, partial enhancement can also be achieved [120] . If the enhancing antibodies are anti-idiotypic for monoclonal antibodies against class I antigens, a similar effect can be seen.
Neither the monoclonal antibodies nor the preformed antiidiotypic antibodies achieved quite as good an enhancing effect as conventional antidonor serum. These latter findings suggest that anti-idiotypic antibodies and monoclonal antibodies may not be completely enhancing if the molecular regions they see are only shared by a single or limited number of alloreactive clones. In a further set of experiments rats pretreated with alloantigen-reactive T lymphoblasts in adjuvant developed antiidiotypic antibodies, reduced lymphocyte reactivity in mixed lymphocyte culture, suppressor T and B cells, cytotoxic T cells for clones reactive to donor antigens, and the ability to carry skin and organ allografts for extended periods [121] [122] [123] [124] [125] [126] . These important and well characterized studies clearly implicate a very complex interplay between the humoral and cell-mediated immune response during the development of anti-idiotypic immunity leading to specific unresponsiveness to donor alloantigens. No one part of the immune system may totally provide the complete suppressive effect.
Immune regulation in human renal disease Experimental studies in animals provide a strong basis for believing that regulatory disturbances may influence the natural history of immune-mediated renal disease in humans. This conclusion is tentative, however, as there are few renal diseases in which the regulatory process has been examined beyond initial cursory observations [8] . The problem of doing this kind of research in humans is compounded by the genetic diversity within the species, the recognition of disease in groups of patients at different stages of development, and a tendency to superimpose only one immunologic mechanism onto a particular pathologic lesion that may be more heterogenous than we presently believe. Despite these qualifications, there is some evidence implicating a role for the immunoregulatory process during the development of renal injury in humans.
Perhaps the earliest observation that altered T cell function may be associated with human glomerulonephritis came from the study of a patient with hereditary thymic dysplasia [241. This individual had hypoplastic lymphoid organs, no germinal centers, a decreased capacity to respond to extrinsic antigens, and an abnormality in the distribution of immunoglobulins. These findings are reminiscent of the defects previously observed in nude mice [127] . The mechanism for the development of glomerulonephritis in this patient would be hypothetically based on a presumed failure in the modulating influence of the T cell repertoire, More than 10 years passed before another study appeared suggesting that patients with nil lesion may have an abnormality in T cell regulation [128] . In a subsequent investigation a lymphokine was found which could alter glomerular permeability to serum proteins [129] . It was postulated that the lymphokine was secreted because of an imbalance in thymic function. Other investigators have also observed a circulating factor in these patients which can suppress the activation of T lymphocytes by mitogens [130] . It has since been reported that patients with nil lesion have increased levels of mitogeninduced suppressor T cells [131] . Although these studies suggest a role for altered T cell function in the pathogenesis of nil lesion, they also only describe nonspecific immunologic effects. In particular, it is unclear as to whether these changes in T cell function are related to the primary stimulus for disease or to something else. A mechanism for the polyclonal suppressive effect was suggested recently by the finding that most patients with nephrotic range proteinuria, regardless of the pathologic lesion, had a decrease in mitogen-induced lymphocyte proliferation [132] . Such findings support the idea that a metabolic defect in nephrotic patients may alter the regulatory function of the immune system.
With the recognition and identification of T cell subsets in humans has come the observation that changes in the normal ratio of T cell subsets in the peripheral blood may characterize certain human kidney diseases [133] . In particular, patients with membranous glomerulonephritis, IgA disease, and focal gbmerular sclerosis seem to have an increase in helper/suppressor cell ratios above normal. Patients with lupus renal disease seem to have a low or normal T cell ratio [18] . Other studies, however, have reported an unpredictable relationship between helper and suppressor T cells in patients with these glomerular lesions [133, 134] . One of the most consistently described defects in T cell subsets nevertheless has been observed in patients with IgA-IgG nephropathy. Blood samples from some of these patients demonstrate elevated amounts of circulating IgA [135] [136] [137] and an increase in IgA-secreting B cells [137, 138] . Preliminary evidence reveals that the suppressor cell subpopulation (OKT8) may be reduced [133] , and that increased IgA production may be associated with a deficiency in IgA-specific suppressor T cells [21] . Given what is known about immunoregulatory circuits, the absence of the suppressor cell subpopulation could prevent patients with IgA-IgG nephropathy from effectively modulating their IgA response. This would leave the disease process in an operationally active mode. While this hypothesis is appealing, not all of the collected data is consistent with this view. Not all patients have an elevated level of circulating IgA, nor an IgA-specific suppressor cell defect [139] . A serial study of a cohort of patients will probably be required to clarify these issues.
For many years systemic lupus erythematosus has also served as a prototype model for immune complex disease producing renal injury in humans. Much has been learned about the role of the systemic immune response in the modulation of immune deposit formation using the previously described autoimmune mice as an experimental frame of reference. It is now clear that human regulatory processes can be as complicated as any observed in these mice. Patients with systemic lupus erythematosus have been studied intensively by a number of immunologic techniques. These individuals produce a variety of autoantibodies including anti-DNA antibodies which can be deposited in gbomeruli from the circulation as complexes or, perhaps, by an in situ mechanism [140, 141] . These patients also have multiple defects within their immunoregulatory systems [18, 142] . Hyperactivity of human lupus B cells [143] , defective suppressor T cell function [18, 142] , and circulating antisuppressor T cell antibodies [144, 145] have all been described. These findings would suggest the immune system in lupus cannot control B cell responses producing pathogenic autoantibodies. The data mentioned so far, however, do not point to a fundamental defect which would predict this wide array of immunologic disturbances. There is some feeling that the immunologic aberrations in this disease are so broad that any attempt to force all the data into a common thread of events might be inappropriate. Nevertheless, a recent study has shown what appears to be an inverse relationship between the presence of anti-idiotypic antibodies to anti-DNA antibodies and the activity of clinical disease [146] . In this study sera was obtained from patients with active disease and from those same patients in remission. Remission sera, depleted of anti-DNA antibodies and free DNA, were able to inhibit the binding of DNA to F(ab')2 fragments of anti-DNA antibodies obtained from active sera. The mechanism for the induction of this anti-idiotypic immunity was not specified. Inhibition was best observed with autobogous remission sera rather than with sera from unrelated inactive patients, suggesting that anti-idiotypic antibodies from one lupus patient may not be directed to the same array of idiotypes expressed by other patients. Of further interest, however, sera from normal individuals previously exposed to lupus patients or lupus blood products could cross-react and inhibit the binding of anti-DNA antibodies from unrelated patients. These normal individuals who occasionally have abnormal serologies [147] may be protected from significant autoreactivity partially by an anti-idiotypic immunity directed against many individual idiotypes as a result of exposure to many different patients or to a common or cross-reactive idiotype, that is, to an idiotype shared by many clones producing anti-DNA antibodies. These findings suggest that normal individuals have a broader anti-idiotypic repertoire than those lupus patients in remission. This difference may, in part, form the basis for susceptibility to the complete expression of disease [19] . A further study of these differences between lupus patients and normal individuals who work with lupus patients may also provide some interesting insight into the regulatory control of autoreactive B cell responses producing immune complex renal disease.
Finally, the topic of immune regulation has now assumed a pre-eminent place among mechanisms for suppressing the nephritogenic immune response leading to allograft rejection. While a variety of drugs has been used to significantly inhibit the development of rejection [114] , it has only recently been observed that some patients may develop active immunologic mechanisms producing graft enhancement. For example, several patients receiving renal allografts have had their immunosuppressive drugs virtually stopped for other reasons [148, 149] . Despite this, they still have been able to carry a functioning transplant for a long period of time. Analysis of their sera has revealed the presence of an antibody which suppresses the mixed lymphocyte reaction between responder and stimulator cells of similar mismatched haplotypes. In proper comparisons these antibodies bound an idiotype expressed by I cell receptors specific for the mixed lymphocyte reaction, suggesting that the idiotype was carried by DR antigen-reactive clones in the recipient. If anti-idiotypic immunity can have an enhancing effect on renal allografts, it would be useful to have a convenient mechanism for inducing this specific form of unresponsiveness to donor alloantigens. Previous experimental work has shown that rats pretreated with donor alloantigens, anti-donor antibodies, or alloantigen-reactive T lymphoblasts all develop an anti-idiotypic immunity leading to transplant enhancement [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] . Such immunization protocols are not as yet really feasible in humans. One alternative immunization protocol has been the use of blood transfusions. Rats pretreated with donorspecific blood have carried grafts for prolonged periods in selected donor-recipient strain combinations [150] . For the last few years, it has been observed that patients receiving various numbers of blood transfusions, probably not just prior but at some point before renal transplantation, have also had better allograft survival [151, 152] . These findings seem to apply to recipients of either living-related or cadaveric transplants. The whole issue of blood transfusions in transplantation has been treated recently by several informative reviews [153, 154] . Although there may be several mechanisms of enhancement [115, 116, 154] , it would seem that blood transfusions can often induce antibodies against a T cell receptor specific for HLA-D/DR antigens [155] . These antibodies will inhibit only certain mixed lymphocyte culture combinations and are probably not directed toward common determinants on the surface of the recipients' T lymphocytes. Furthermore, patients who maintain long-term functioning allografts have had these antibodies, whereas patients rejecting their grafts have not [l56j. The induction of anti-idiotypic immunity following transfusion may be marked by the development of anti-idiotypic antibodies, but the actual mechanism of enhancement may be more complex.
Reports of inducing suppressor cells following transfusion [157] may, in fact, be just another aspect of the anti-idiotypic repertoire.
Transfusion-induced anti-idiotypic immunity may have several implications for donor-recipient selection. First, potential transplant recipients receiving unselected blood transfusions may only see a beneficial effect if the suitability of the donor is predicated on the presence of anti-idiotypic antibodies which can inhibit that particular donor-recipient mixed lymphocyte reaction [156] . This observation may have special importance when more than one living-related donor is available, or when one or more recipients of a mismatched cadaveric transplant are in the process of being selected. Second, donor-specific transfusions may be a useful way to target specific graft enhancement [152] . Whether such transfusions are necessary in all recipientdonor combinations remains to be seen [153] .
The aforementioned observations present more evidence that further studies of regulatory function in immune-mediated renal disease in humans should be pursued with renewed interest. The technical feasibility of such studies continues to improve, and on-going experiments in animals create a firmer basis for enhancing the designs of future human investigations.
Concluding remarks
The nephritogenic immune response can be mechanistically defined both at the effector level within the kidney and in terms of alterations in highly organized regulatory circuits. Recognized defects in these antibody and cell-mediated circuits may permit the mediators of immunopathology to continue damaging the kidney at the local level. The descriptions of regulatory processes involving T cells and anti-idiotypic immunity are new and extremely complex. As more information accumulates, it is very apparent that many regulatory components are more integrated than separate. The future mold of this area of research, however, depends heavily on more basic studies in animal models. An examination of regulatory functions at this level and, in these terms, can only promise new and potentially exciting information. Such studies may ultimately demonstrate how selective modulation of the nephritogenic immune response may be used to diminish host morbidity or even provide effective immunoprophylaxis.
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Germ-line genes, highly conserved immunogenetic information passed to progeny by germ cells (sperm and egg). Immune response genes, genes usually found in the major histocompatability complex which determine an individual's ability to immunologically respond to complex antigens, Variable region genes, genes which code for the protein sequences that deter-mine both the structural basis for antigen-binding as well as the expression of idiotypes. Idiotope, a unique protein determinant expressed by variable region genes. Interestingly enough, and for enigmatic reasons, the genes which code for the variable region idiotopes on antibody molecules do not seem to be the same genes which code for idiotopes expressed by T cells showing a similar antigen-binding specificity. Individual idiotypes, a collection of unique protein determinants expressed by a very limited number of T or B cells with the same antigenbinding specificity. Cross-reactive idiotypes, a collection of unique protein determinants expressed by a frequent number of T or B cells with the same antigen-binding specificity. These idiotypes may be important regulatory molecules. Clonotype, identical cell replicates derived from a single ancestor. MHC, major histocompatability complex; in humans it is designated HLA, in mice H-2, and in rats RT1. Genes in this complex 
